Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Retreatment Rhenium Liposome · 1 trial · 1 indication
Safety and tolerability assessed by number of participants with treatment-related toxicities and/or adverse events as assessed by CTCAE v4.0 with 4-week evaluation periods for toxicity and disease assessment until disease progression is suspected.
To assess overall survival following 186RNL in patients with bevacizumab naïve recurrent glioblastoma following treatment with a second administration of 186RNL.
| Arm | Type | Description |
|---|---|---|
| Retreatment with Rhenium Liposome | EXPERIMENTAL | Each participant will receive a single administration of 186RNL. The proposed dose is up to 8.8 mL as a single administration with an administered dose of 22.3 mCi. |
| Name | Type | Description |
|---|---|---|
| Retreatment Rhenium Liposome | DRUG | At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI. |
Inclusion Criteria: 1. At least 18 years of age at time of screening. 2. Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB. 3. Patient must present with biopsy and histology proven glioma following initial ...